Prescribing “Placebo Treatments”: Results of National Survey of US Internists and Rheumatologists by Tilburt, Jon C et al.
 
Prescribing “Placebo Treatments”: Results of National Survey of
US Internists and Rheumatologists
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Tilburt, Jon C., Ezekiel J. Emanuel, Ted J. Kaptchuk, Farr A.
Curlin, and Franklin G. Miller. 2008. Prescribing “placebo
treatments”: Results of national survey of US internists and
rheumatologists. British Medical Journal 337: a1938.
Published Version doi:10.1136/bmj.a1938
Accessed February 19, 2015 7:08:05 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8255741
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH
Prescribing “placebotreatments”:resultsofnationalsurvey
of US internists and rheumatologists
JonCTilburt,staffscientist,
1EzekielJEmanuel,director,
1 TedJKaptchuk,associatedirector,
2 FarrACurlin,
assistant professor of medicine,
3 Franklin G Miller, director, research ethics programme
1
ABSTRACT
Objective To describe the attitudes and behaviours
regarding placebo treatments, defined as a treatment
whose benefits derive from positive patient expectations
and not from the physiological mechanism of the
treatment itself.
Design Cross sectional mailed survey.
Setting Physicians’ clinical practices.
Participants 1200 practising internists and
rheumatologists in the United States.
Main outcome measures Investigators measured
physicians’ self reported behaviours and attitudes
concerning the use of placebo treatments, including
measuresofwhethertheywoulduseorhadrecommended
a “placebo treatment,” their ethical judgments about the
practice,whattheyrecommendedasplacebotreatments,
and how they typically communicate with patients about
the practice.
Results 679 physicians (57%) responded to the survey.
Abouthalfofthesurveyedinternistsandrheumatologists
reported prescribing placebo treatments on a regular
basis (46-58%, depending on how the question was
phrased). Most physicians (399, 62%) believed the
practice to be ethically permissible. Few reported using
saline (18, 3%) or sugar pills (12, 2%) as placebo
treatments, while large proportions reported using over
the counter analgesics (267, 41%) and vitamins (243,
38%) as placebo treatments within the past year. A small
but notable proportion of physicians reported using
antibiotics(86,13%)andsedatives(86,13%)asplacebo
treatments during the same period. Furthermore,
physicians who use placebo treatments most commonly
describe them to patients as a potentially beneficial
medicine or treatment not typically used for their
condition (241, 68%); only rarely do they explicitly
describe them as placebos (18, 5%).
Conclusions Prescribing placebo treatments seems to be
commonandisviewedasethicallypermissibleamongthe
surveyedUSinternistsandrheumatologists.Vitaminsand
over the counter analgesics are the most commonly used
treatments.Physiciansmightnotbefullytransparentwith
their patients about the use of placebos and might have
mixed motivations for recommending such treatments.
INTRODUCTION
The use of placebo treatments in clinical medicine is
ethically controversial.
12 The placebo effect refers to
positiveclinicaloutcomescausedbyatreatmentthatis
not attributable to its known physical properties or
mechanism of action. The placebo effect is often
explained as the result of positive expectation, belief,
or hope in patients derived from the clinical
encounter.
34
Before 1960, administration of inert substances to
promote placebo effects or to satisfy patients’ expecta-
tionsofreceivingaprescribedtreatmentwascommon-
place in medical practice.
5-13 With the development of
effective pharmaceutical interventions and the
increased emphasis on informed consent, the use of
placebo treatments in clinical care has been widely
criticised.Prescribinga placebo,it is claimed,involves
deception and therefore violates patients’ autonomy
and informed consent.
1415 Advocates of placebo
treatments argue that promoting the placebo effect
mightbeoneofthemosteffectivetreatmentsavailable
for many chronic conditions and can be accomplished
without deception.
16-19
“Placebo treatment” is an unclear and complicated
concept that lacks a standard definition. Placebo
treatments include “inert” agents that have little or no
pharmacological activity, such as sugar pillsand saline
injections given to promote positive expectation, and
physiologically active agents, such as vitamins or
antibiotics, that the physician prescribes solely or
primarily to promote positive psychological effects.
16
Furthermore, clinicians might recommend an “active”
treatment to elicit a possible pharmacological effect
and a placebo response simultaneously. Given these
and other terminological difficulties,
3 for the purposes
of our research we defined a “placebo treatment” as a
treatment whose benefits (in the opinion of the
clinician) derive from positive patient expectations
and not from the physiological mechanism of the
treatment itself.
Despite the persistent controversy surrounding the
useofplacebotreatments,therearefewsystematicdata
concerning physicians’ attitudes towards and use of
placebo treatments in the United States.
20-22 The few
contemporary surveys from other countries suggest
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To further inform ethical discussions about the
appropriatenessofrecommendingplacebotreatments,
we examined the attitudes and behaviours regarding
placebo treatments among a national sample of
clinically active internists and rheumatologists in
the US.
METHODS
Study population
Using the 2006 American Medical Association mas-
terfile, we randomly selected 1200 physicians listed
with the primary specialties of internal medicine (600)
or rheumatology (600): a group of physicians who
commonly treat patients with debilitating chronic
clinical conditions that are notoriously difficult to
manage. Participants were screened to determine if
they were currently practising. In June 2007, an
independent survey research firm posted a confiden-
tial, self administered survey, a $20 (£11, €15)
incentive, and a letter outlining the voluntary nature
of participation. Participants were assured that their
identities would not be disclosed to investigators.
Those who did not respond to the first survey were
sent a second six weeks later. Response rates were
calculated with standard conservative survey research
definitions (RR1 from the American Association for
Public Opinion Research).
28 Of the 1200 physicians
who were sent questionnaires, 679 responded (overall
responserate57%),ofwhom334specialisedininternal
medicine(56%responserate)and345inrheumatology
(58% response rate).
Survey instrument
The questions on use of placebo treatment were
incorporated into a survey that covered other topics
related to complementary and alternative medicine
(details available on request). The survey was devel-
opedthroughaformalprocessandincludedareviewof
existing surveys on the use of placebo treatments.
2324
Because the term “placebo” and behaviours surround-
ing its use can be contentious, we devised a series of
non-judgmental questions beginning with broad ques-
tions that avoided the term “placebo” and then
gradually gained more specificity, culminating in
items whose responses used a clear definition of a
“placebo treatment.” By constructing a series of items
in this manner we allowed respondents to describe
their attitudes and experiences as accurately as
possible.
The first set of three items began witha hypothetical
scenario in which a dextrose tablet was shown in
clinical trials to be superior to a no treatment control
group (thus establishing its efficacy as a placebo
treatment). To avoid biasing responses these three
questions did not use the term “placebo,”“ placebo
treatment,”or“placeboeffect.”Respondentswerethen
asked to rate the likelihood of their personally
recommending this treatment to non-diabetic patients
with fibromyalgia; how often they recommend a
therapy“primarilybecauseyoubelieveitwillenhance
the patient’s expectation of getting better”;a n d
whether recommending treatments in this manner
was “obligatory,”“ permissible,”“ permissible in rare
circumstances,” or “never permissible.” Respondents
werethenaskedtoindicatewhichofseveraltreatments
they had used within the past year primarily as a
placebo treatment, defined as a treatment whose
benefits derive from positive patient expectations and
notfromthephysiologicalmechanismofthetreatment
itself; and how they typically described placebo
treatments to patients. By asking these five questions
both without the term “placebo” and then using the
term, we aimed to assess physicians’ practices as
accurately as possible.
Data management and analysis
All data were double entered and 100% verified. We
used descriptive statistics to examine physicians’
characteristics as well as frequencies of reported
behaviours and attitudes. Percentages reported are
based on actual numbers of respondents. All 679
respondentsanswered most questions. We used multi-
variate logistic regression to determine if any char-
acteristics of participants were independently
associated with regularly prescribing placebo treat-
ments. For this analysis our dependent variable was
recommending treatments “primarily to promote
patient expectations” at least two to three times a
month based on self reporting. All analyses were
conducted with STATA (version 8.0).
Table 1 |Characteristicsof679USphysiciansquestionedabout
useofplacebos.Figuresarenumbers(percentages)of
responsesapartfromage
Characteristics No (%)*
Mean (range) age (years) 51 (28-88)
Male 477/652 (73)
Race/ethnicity:
Asian 89/648 (14)
African American 14/648 (2)
White 526/648 (81)
Other 19/648 (3)
Specialty:
Internal medicine 334/679 (49)
Rheumatology 345/679 (51)
Practice setting:
Solo 186/679 (27)
Group 334/679 (49)
Institutional 28/679 (4)
Academic 96/679 (14)
Other 24/679 (4)
Region:
South 253/679 (37)
North east 219/679 (32)
Midwest 108/679 (16)
West 99/679 (15)
*Percentages based on actual numbers of respondents as shown.
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The mean age of the 679 respondents was 51 years
(range28-88),73%(477/652)weremen,and81%(526/
648)werewhite.Overall,respondentsmostcommonly
reported a group practice setting (49%, 334/679),
followed by solo practice (27%, 186/679), academic
(14%, 96/679) and institutional (4%, 28/679). The
largest proportions of respondents practised in the
south (37%, 253/679) and the north east (32%, 219/
679) (table 1). Respondents and non-respondents did
not differ significantly according to age, sex, race,
practice setting, or specialty.
When asked if they would recommend a dextrose
tabletforapatientwithfibromyalgiaiftrialshadshown
such treatment to be superior to no treatment, most
respondents (58%, 381/654) said they would be very
likelyormoderatelylikelytorecommendit.Similarly,
46% (298/646) reported actually recommending a
treatmentprimarilytopromotepatientexpectationsat
least two to three times a month. The physicians’
ethical judgments were also favourable toward the use
of placebo treatments, and 62% (399/642) said
recommendingtreatmentsinthismannerwasethically
obligatory or permissible (table 2).
Within the previous year, 55% of (370/679) physi-
cians reported having recommended at least one
placebo treatment (including “active” and “inactive”).
Active placebo treatments were more commonly
reported, such as over the counter analgesics (41%),
vitamins (38%), antibiotics (13%), and sedatives (13%).
Only 2% recommended “sugar pills” and 3% saline
(table 3).
Whenaskedtodescribehowtheytypicallyintroduce
placebo treatments to their patients, 45% (285/637)
reported never recommending placebo treatments,
implying that 55% (352/637) agreed that they had
recommendedaplacebotreatmentasdefined.Among
these 352, about 68% (241) said they usually describe
placebo treatments as “a medicine not typically used
for your condition but might benefit you,” 18% (62)
introducedplacebotreatmentsas“amedicine,”and9%
(31) said they typically describe placebo treatments as
“amedicinewithnoknowneffectsforyourcondition.”
Only 5% (18) reported typically describing the treat-
ment as “a placebo” (table 3).
After we controlled for all other characteristics,
neither age, sex, race, specialty, practice setting, nor
regionwereindependentlyandsignificantlyassociated
with having recommended a placebo treatment
(table 4).
DISCUSSION
Summary of major findings
Abouthalfofthe679USinternistsandrheumatologists
questionedreportedprescribingplacebotreatmentsto
their patients on a regular basis. Many of these
physicians were favourably disposed to recommend-
ing or prescribing placebo treatments. Most said they
would prescribe a sugar pill for patients with a chronic
painful condition if there was evidence of placebo
efficacy, and nearly half said they had used treatments
primarily to promote positive expectations in their
patients more than once in a month. In addition, most
US internists and rheumatologists believe that recom-
mending treatments because they promote such
expectations is ethically permissible. Once given a
clear definition, over half said they had recommended
atleastonetreatmentwithinthepastyearasa“placebo
treatment.” In some circumstances common innoc-
uous treatments—such as vitamins or over the counter
analgesics—are used; in other circumstances physi-
cians use antibiotics and sedatives as placebo treat-
ments. Furthermore, physicians most often describe
placebo treatments to patients as a potentially bene-
ficial medicine or treatment, rarely describing them as
placebos.
Table2 |Attitudesandbehavioursrelatedtoprescribingplacebosamong679USgeneralinternists
andrheumatologists
Question and categories of response No (%*)
How likely are you to recommend sugar pill proved to be better than no treatment for fibromyalgia?:
Very likely 160/654 (24)
Moderately likely 221/654 (34)
Unlikely 205/654 (31)
Definitely not 68/654 (10)
How often do you recommend treatment primarily to enhance patient expectation?:
Never 129/646 (20)
≤1/month 219/646 (34)
2-3/month 182/646 (28)
≤1/week 116/646 (18)
Is it appropriate to recommend treatment primarily to promote patients’ expectations?:
Obligatory 19/642 (3)
Permissible 380/642 (59)
Permissible only in rare circumstance 197/642 (31)
Never permissible 46/642 (7)
*Based on actual numbers.
Table 3 |Treatmentsusedasplaceboinpastyearandhowtheyaredescribedtopatientsamong
679USgeneralinternistsandrheumatologists
Question and response items No (%*)
Recommended as “placebo treatment” in past year:
At least one of any type 370/679 (55)
Over counter analgesics 267/648 (41)
Vitamins 243/648 (38)
Sedatives 86/652 (13)
Antibiotics 85/644 (13)
Saline 18/623 (3)
Sugar pills 12/642 (2)
How placebo treatments are typically described to patients:
Not used 285/637 (45)
Medicine 62/352 (18)
Placebo 18/352 (5)
Medicine with no known effects for your condition 31/352 (9)
Medicine not typicallyusedfor yourcondition but mightbenefit
you
241/352 (68)
*Based on actual numbers of respondents. All 679 respondents answered most questions. Percentages reflect
352 responses of 637 respondents who deemed the question relevant. The 285 respondents who marked
“irrelevant—I do not prescribe placebo treatments” were not included in these percentages.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 5Between 46% and 58% of US internists and
rheumatologists engage in recommending placebo
treatments as defined. This large empirical study
examined attitudes and behaviours among practising
physicians toward recommending placebo treatments
and used a systematic, random, national sample. To
accurately assess attitudes and behaviours relating to
placebo treatments, we asked the physicians about
recommending placebo treatments in four distinct
ways: response to a hypothetical case, self reported
behaviour without the term “placebo treatment,” self
reportedbehaviourwiththeterm“placebotreatment,”
and inclusion of “I never use placebo treatments” as a
response option in our item related to communication
withpatients.Thefirsttwoofthesewereaskedwithout
introducing the term “placebo” to allow the most
candid and unbiased responses. The third and fourth
were asked after a careful definition of a “placebo
treatment.”Thesimilarratesacrossthesefourdifferent
measures indicate that our findings are unlikely to be
the result of question framing, wording, or the specific
definition of placebo treatment used.
Relation to other studies
Our results are consistent with the findings of other
studies. Recently, Sherman and Hickner surveyed a
conveniencesampleof231academicphysiciansinthe
Chicago area and found that 45% had used placebo
treatments in clinical practice.
22 Indeed, 8% indicated
usingplacebotreatmentmorethan10timesinthepast
year.ADanishsurveyreportedthat86%of545general
practitioners used a placebo treatment at least once
within the past year, and 48% reported using placebo
treatments more than 10 times in the past year.
23
Smaller surveys from Israel, the UK, Sweden, and
New Zealand report similar results.
24-27
Unresolved questions raised by this study
Understanding the role of placebo treatments in
contemporary medicine is complex. Promoting posi-
tive expectations in patients has historically been an
important part of the physician’s therapeutic role,
though the current major role of drug treatment is
undeniable. Few of the physicians we surveyed
recommend inert placebo treatments. The reasons for
this are unclear. It might no longer be possible for
physicians to write a prescription for a sugar or bread
pill.Withouttheexistenceofpharmaciestocreatesuch
pills, and a lack of actual pills being marketed for such
use, physicians could not prescribe them routinely
even if they wanted to do so. Or they might have
understandable reservations about recommending so
called “inactive”or “inert” placebotreatments,fearing
these treatments are inherently deceptive and are not
amenable to contemporary standards of informed
consent.
Yet these data also suggest the desire to promote
positive therapeutic expectations among patients is
prevalent among the surveyed physicians. The
responses suggest a preference for active placebo
treatments. Physicians might have multiple, possibly
conflicting,beliefsandmotivationsforrecommending
active placebo treatments. They might believe that a
given benign and safe treatment, such as some
indicated by our respondents (for example, vitamins
and over the counter analgesics), might have some
finite chance of a beneficial pharmacological effect,
despite remaining unproved for the symptoms or
conditionathand;or,attheveryleast,suchtreatments
mightpromotepositiveexpectationsinpatientsorhelp
thepatienttofeelliketheyarebeingtakencareof.This
perceivedneedtoadministersomethingintheabsence
of other proved effective treatments for chronic
symptomatic conditions (that promotes a sense of
treatment options and positive expectations in
response to patients’ complaints) might motivate
physicians to prescribe placebo treatments.
29 We did
not explore these complex beliefs and motives in this
survey.
Recommending relatively innocuous treatments
such as vitamins or over the counter analgesics to
Table 4 |CharacteristicsofUSinternistsandrheumatologists
independentlyassociatedwithhavingrecommendedplacebo
treatmentatleast2-3times/month
Characteristics Odds ratio* (95% CI)
Age 0.99 (0.97 to 1.01)
Male 0.76 (0.52 to 1.11)
White race 1.32 (0.85 to 2.06)
Specialty:
Internal medicine 0.82 (0.58 to 1.16)
Rheumatology —
Practice setting:
Solo —
Group 0.97 (0.66 to 1.43)
Institutional 0.72 (0.31 to 1.66)
Academic 0.73 (0.43 to 1.23)
Other 0.96 (0.40 to 2.35)
Region:
North east —
South 1.47 (0.99 to 2.16)
Midwest 0.72 (0.43 to 1.21)
West 1.01 (0.61 to 1.71)
*Based on responses of 637 observations included in model.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Recommendingtreatmentsto promote patients’ expectations (placebo treatments) seems to
be common in several developed countries
The routine use of placebo treatments raises ethical questions about deception in clinical
practice
WHAT THIS STUDY ADDS
Half of the US internal medicine and rheumatology physicians studied reported often
recommending placebo treatments, most commonly vitamins, over the counter analgesics,
and antibiotics
Most viewed this practice as ethically permissible
Physiciansmightnotbefullytransparentwiththeirpatientsabouttheirmotivationsbutlargely
avoid prescribing sugar pills and saline
RESEARCH
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concernsaboutdetrimentaleffectstopatients’welfare.
Prescribingantibioticsandsedativeswhentheyarenot
medically indicated, however, could have potentially
important adverse consequences for both patients and
public health. In the absence of knowing the physi-
cians’ indication or motivation for recommending
placebo treatments, the interpretation of our findings
remains speculative. These issues deserve further
investigation to examine motivations, beliefs about
the efficacy of placebo treatments, and the range of
circumstancesinwhichtheyareusedamongabroader
sample of physicians.
There are many different descriptive terms used to
refer to patients’ expectations of healing in clinical
medicine and treatments that intersect with those
expectations but “placebo treatment,” as defined and
used in this study, is an understandable term that best
captures this clinical phenomenon.
Study limitations
This study has several limitations. The cross sectional,
self reported design might not have accurately
estimated the actual frequency of recommending
placebo treatments. The moderate response rate
(57%) also limits our ability to make exact estimates
of the behaviour in the entire population of these
groups of physicians; and our findings might not be
generalisable to attitudes and behaviours in other
medical specialties. Furthermore, because these items
were included in a survey on complementary and
alternative medicine, it is possible that the physicians
who chose to respond were more favourably disposed
to prescribe placebo treatments than most physicians.
However,ourfindingsareconsistentwiththeresultsof
other published studies concerning physicians’ use of
placebo treatments.
Conclusions
US internists and rheumatologists commonly recom-
mend “placebo treatments.” Vitamins and over the
counteranalgesicsarethemostcommonlyprescribed.
Physicians who use placebo treatments may not be
fully transparent with their patients about their use.
Whether, or under what circumstances, recommend-
ing or prescribing placebo treatments is appropriate
remains a topic for ethical and policy debates.
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